|
11 Companies |
|
5 Products |
|
5 Products |
|
5 Mechanisms of Action |
|
0 Trials |
|
118 News |
|
| «123 |
- Trial initiation date: Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines (clinicaltrials.gov) - Feb 27, 2013
P=N/A, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Initiation date: Jan 2013 --> Aug 2013
- Zostavax (zoster vaccine live) / Merck (MSD)
Enrollment change: Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study (clinicaltrials.gov) - Feb 27, 2013
P1/2, N=0, Withdrawn, Sponsor: University of Zurich
Initiation date: Jan 2013 --> Aug 2013 N=150 --> 0
- Enrollment change: Immune Response to Varicella-Zoster Vaccination and Infection (clinicaltrials.gov) - Jan 16, 2013
P=N/A, N=19, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=150 --> 0 N=310 --> 19
- Trial completion: Immune Response to Varicella-Zoster Vaccination and Infection (clinicaltrials.gov) - Jan 16, 2013
P=N/A, N=19, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=310 --> 19 Recruiting --> Completed
- Biomarker, New P1 trial: Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines (clinicaltrials.gov) - Jan 8, 2013
P1, N=24, Recruiting, Sponsor: University of Surrey
- Enrollment closed: Scrambler Therapy in Treating Chronic Pain in Patients With Rash From Varicella Zoster Virus Infection (clinicaltrials.gov) - Nov 26, 2012
P=N/A, N=10, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Zostavax (zoster vaccine live) / Merck (MSD)
Enrollment open, IO biomarker: Zoster Vaccine Response in the Frail Elderly (clinicaltrials.gov) - Oct 23, 2012
P=N/A, N=250, Recruiting, Sponsor: McMaster University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- inactivated VZV vaccine (V212) / Merck (MSD)
Trial completion: A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013) (clinicaltrials.gov) - Oct 1, 2012
P1, N=80, Completed, Sponsor: Merck
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Enrollment change: Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles (clinicaltrials.gov) - Sep 24, 2012
P=N/A, N=68, Completed, Sponsor: Pascoe Pharmazeutische Praeparate GmbH
Active, not recruiting --> Completed N=350 --> 68
- | New P4 trial: Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin (clinicaltrials.gov) - Sep 10, 2012
P4, N=1200, Completed, Sponsor: Beijing Center for Disease Control and Prevention
- ||| Varivax (varicella virus vaccine live) / Merck (MSD)
Trial completion: Re-examination Study For Varivax (V210-059 AM2) (clinicaltrials.gov) - Jun 28, 2012
P=N/A, N=754, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=350 --> 68 Active, not recruiting --> Completed
- |||||||||| Varivax (varicella virus vaccine live) / Merck (MSD)
New P3 trial: A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX (clinicaltrials.gov) - Jun 21, 2012
P3, N=520, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Varivax (varicella virus vaccine live) / Merck (MSD), ProQuad (measles, mumps, rubella and varicella virus vaccine live) / Merck (MSD)
Trial termination: A Study of ProQuad (clinicaltrials.gov) - Feb 20, 2012
P3, N=30, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Suspended --> Terminated; Study terminated early because of insufficient enrollment before expiration date of the investigational vaccine lot
- Varivax (varicella virus vaccine live) / Merck (MSD), ProQuad (measles, mumps, rubella and varicella virus vaccine live) / Merck (MSD)
Enrollment change: A Study of ProQuad (clinicaltrials.gov) - Feb 20, 2012
P3, N=30, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Suspended --> Terminated; Study terminated early because of insufficient enrollment before expiration date of the investigational vaccine lot N=360 --> 30
- |||||||||| ProQuad (measles, mumps, rubella and varicella virus vaccine live) / Merck (MSD)
New P3 trial: Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) (clinicaltrials.gov) - Feb 20, 2012
P3, N=1413, Completed, Sponsor: Merck Sharp & Dohme Corp.
- ||||| inactivated VZV vaccine (V212) / Merck (MSD)
New P2 trial: A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009) (clinicaltrials.gov) - Feb 5, 2012
P2, N=354, Completed, Sponsor: Merck Sharp & Dohme Corp.
- |||||||||| New P3 trial: Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children (clinicaltrials.gov) - Jan 5, 2012
P3, N=720, Active, not recruiting, Sponsor: GlaxoSmithKline
- Zostavax (zoster vaccine live) / Merck (MSD)
New P1 trial: Zostavax in Systemic Lupus Erythematosus (clinicaltrials.gov) - Nov 16, 2011
P1, N=20, Completed, Sponsor: Oklahoma Medical Research Foundation
- inactivated VZV vaccine (V212) / Merck (MSD)
New P1 trial: A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013) (clinicaltrials.gov) - Oct 25, 2011
P1, N=80, Completed, Sponsor: Merck
- | Trial completion: SPS: Shingles Prevention Study (clinicaltrials.gov) - Aug 7, 2011
P3, N=38456, Completed, Sponsor: Department of Veterans Affairs
N=360 --> 30 Active, not recruiting --> Completed